GNBT - Generex Biotechnology Corporation (NasdaqCM: GNBT) Tomo UNO


Punti reazioni
Generex Biotechnology Corporation Reports Significant Advance in Cancer Immunotherapy Based Upon Boosting T Helper Cell Responses by Novel Mechanism
PR Newswire - April 06, 2004 08:45
Novel Prostate Cancer Treatment Cures 50% of Mice in Advanced Preclinical Trial and Offers Potent Therapy for Recurrent Disease

TORONTO, Apr 6, 2004 /PRNewswire-FirstCall via COMTEX/ -- Generex Biotechnology Corporation (Nasdaq: GNBT), announced today its recent report at the American Association for Cancer Research in Orlando, Florida on a novel approach to cancer vaccination developed by scientists and collaborators at its Antigen Express subsidiary. About 1,500 cancer clinicians and researchers from around the world attended this conference.

Dr. Eric von Hofe, Vice President, Technology Development at Antigen Express, who presented this report, said: "This technology is revolutionary in the sense that we bioengineer cancer cells to present their antigenic epitopes directly to T helper lymphocytes. That process improves the speed and power of antigenic stimulation of the T helper cells. In turn, there is a better cytotoxic T lymphocyte and antibody response to the tumor."

The Antigen Express technology induces special receptors for endogenous tumor antigenic peptides, the Major Histocompatibility Complex class II molecules, in the absence of the immunoregulatory Ii protein. Peptides containing antigenic epitopes of the tumor become bound to the MHC class II molecules at the time of their synthesis in the endoplasmic reticulum. Such peptide/MHC class II complexes become presented to T cells at the surface of the cancer cell. Without this novel bioengineering method the peptide/MHC class II complexes may never form, or if they do are present in much lower abundance.

The Antigen Express method cures about half of the mice treated in advanced preclinical animal studies. The model employs an aggressive, poorly immunogenic prostate cancer. Development is proceeding in animal models and for clinical grade materials to treat prostate, breast, colon, and lung cancers and melanoma. Dr. von Hofe said: "I am very pleased with the interest and active collaborations we are developing with outstanding investigators at premium Cancer Centers."

"We are finding revolutionary, not evolutionary solutions to major medical problems," said Anna Gluskin, Chief Executive Officer of Generex. "We have achieved that in RapidMist delivery of insulin. We have acquired the novel immunotherapeutic platforms of Antigen Express because there are important synergies. These synergies lie in the use of RapidMist technology to deliver the drugs being developed by Antigen Express. In some cases, we think RapidMist is the only practical way to deliver those drugs. That is, when high frequency, low dose, immunomodulating peptide must be delivered to control autoimmune diseases such as multiple sclerosis or diabetes, the needle-less, convenient RapidMist method will be preferred by patients and their physicians."

About Generex

Generex is engaged in the research and development of drug delivery systems and technology. To date, it has focused on developing a platform technology for the buccal delivery -- delivery to the oral cavity for absorption through the inner mouth mucosa -- of drugs that historically have been administered only by injection. Generex's buccal delivery technology has application to a large number of drugs. Generex acquired Antigen Express in August 2003. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases.

This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward- looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward- looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
aloaaaaaaaaaa sopra i 2$ si puo tentare
che dite si può iniziare a compricchiare qualcosa ? con tutta la m@rd@ che vola volerà anche questa ? :D :D :yes:


  • Anonimo.jpg
    83,5 KB · Visite: 255
oggi mi farò un giro sulla ciofeca del baffone
e dai che mi viene a prendere 1,2, queste sono le soddisfazioni del trading 5 min e via ehhehehhehehehh
mi sono rimesso a 1,11 stop 1,01 se dovessi risalire rischio solo il gain ma mi son divertito ehehhehehehhe vediamo :D
azz preso, ehhehehe veloce la bimba vediamo murble murble hehehehe
Grecale ha scritto:
azz preso, ehhehehe veloce la bimba vediamo murble murble hehehehe

ciao Lucien,,complimenti x il tempismo!!!!

intanto la news è ottima OK!

Generex Biotechnology to Accelerate Development of Vaccine for Pandemic Avian Influenza
Wednesday October 19, 9:23 am ET

Novel Vaccine Technology Boosting T Helper Cell Response to Asian Bird Flu Influenza Promises Increased Population Protection

TORONTO--(MARKET WIRE)--Oct 19, 2005 -- Generex Biotechnology Corporation (NasdaqSC:GNBT - News) announced today that Antigen Express, Inc., its wholly owned immunotherapeutics subsidiary, has re-organized its forces to speed development of a novel vaccine to protect against the H5N1 avian influenza. In particular, the President of Antigen Express, Eric von Hofe, will focus his efforts and those of the Company on bringing this new vaccine into the clinic in the shortest time possible. A similar vaccine peptide, designed using a portion of a protein expressed in breast cancer cells modified with Ii-Key, is currently in clinical trials at the Walter Reed Army Medical Center.

"The threat of a pandemic by avian influenza has made it clear that yesterday's vaccine technologies are woefully insufficient," said Eric von Hofe, President of Antigen Express. "The vaccines being developed at Antigen Express have a clear role to play in responding to threats posed by agents such as H5N1 influenza."

A major drawback to current vaccine development efforts is the inability to manufacture enough vaccine in the event of an avian flu pandemic. Current estimates are that the total production capacity of the world for producing an avian flu vaccine using traditional methods is less than 40 million doses, at the cost of several 100 million dollars. A compounding problem in developing vaccines for the avian flu is that two doses are required to achieve protective immunity given that people have never been exposed to a flu virus similar enough to impart even partial immunological protection. Further, they can be produced in nearly limitless quantities using entirely synthetic means in existing facilities.

The great advantage of the Antigen Express vaccine is the ability to expand and strengthen the T helper cell response to a lower dose of classically produced vaccine. The Ii-Key/H5 hybrids can be synthesized less expensively and in large quantities. It is also expected that the vaccine hybrids will afford some significant degree of protection in humans who have received no other vaccine.

Scientists at Antigen Express are developing a vaccine for the potentially pandemic Asian bird flu (H5N1 strain), utilizing highly conserved fragments of the H5 protein to stimulate potent T-helper cell activity. This is important, as a strong T-helper response plays a major role in helping the body to develop neutralizing antibodies to the influenza virus. The H5 fragments are modified using a portion of an immunoregulatory protein (termed Ii-Key) that greatly facilitates their ability to stimulate T-helper cell responses specific to the H5N1 strain. The vaccine peptides have been selected for their likelihood of being both potent and active in more than 80% of the population.

Antigen Express scientists designed and synthesized a panel of 24 Ii-Key/H5 hybrid vaccine peptides, using computer-modeling predictions to identify those with the greatest chance of being active in diverse populations. Recently completed studies demonstrated that T helper cells from mice immunized with recombinant H5 protein or H5 DNA responded strongly in INF and IL-4 ELISPOT assays to three Ii-Key/H5 hybrids, indicating that the natural response to H5 protein involved T helper cell recognition to three of the H5 peptides we had designed. Subsequent experiments demonstrated that immunization of mice with the three Ii-Key/H5 hybrids alone also lead to strong T cell responses.
Ciao palm :), meglio cosi ehehheheh belle montagne russe ;)
olà lu' tutto bene?:)

avrei un paio di target a 1.33-1.35...
poi c'è un altro a 1.94 ma mi smebra troppo...
strategia mordi e fuggi pero'...
si sa mai co sti bidoni...:)

vediamo se riesco ad entrare
ok siamo sul 50% dal close di ieri...
ciao gnappo :), azz lo stop 1,01 ha retto di un pelo ha ritoccato 1,02 adesso sembra riprendere ;) se supera 1,2 i tp sono giusti ;)
Superando 1,13 riprende a correre, tra 1.09 e 1,12 ha scambiato milioni di pezzi
preso lo stop. però che kaz di giornata cmq 10tik per il caffè sono rimasti, vediamo se il close ispira.........ehehhehe na tazzulella è cafe
Uazz ke cavallo imbizzarrito! :eek:

x me è interessante se tiene 1$ o sui livelli di Fibo che ho indicato

P.S. cmq sti titoli quando esce la news dei livelli se ne stra-fregano... quindi meglio tenerli buoni x l'intra-day


  • GNBT_D3M 19Oct05.PNG
    GNBT_D3M 19Oct05.PNG
    22,2 KB · Visite: 196
bel chart, attiva in pre, possibile run occhio ;)
rientrato 1,28, qui il chart è bello vediamo un pò se dura più di un giorno.....